📗 Cite This Artifact
Accelerating Medicines Partnership Alzheimer's Disease (AMP-AD)
Accelerating Medicines Partnership Alzheimer's Disease (AMP-AD)
Introduction
The Accelerating Medicines Partnership Alzheimer's Disease (AMP-AD) is a precompetitive consortium that brings together academic researchers, pharmaceutical companies, and patient advocacy organizations to identify and validate novel therapeutic targets for [Alzheimer's Disease](/diseases/alzheimers-disease). The partnership generates and shares large-scale multi-omics data to accelerate drug discovery.
Background
Partnership Structure
AMP-AD was launched by the NIH in 2014 as part of the Accelerating Medicines Partnership (AMP) initiative:[@amp2024]
Accelerating Medicines Partnership Alzheimer's Disease (AMP-AD)
Introduction
The Accelerating Medicines Partnership Alzheimer's Disease (AMP-AD) is a precompetitive consortium that brings together academic researchers, pharmaceutical companies, and patient advocacy organizations to identify and validate novel therapeutic targets for [Alzheimer's Disease](/diseases/alzheimers-disease). The partnership generates and shares large-scale multi-omics data to accelerate drug discovery.
Background
Partnership Structure
AMP-AD was launched by the NIH in 2014 as part of the Accelerating Medicines Partnership (AMP) initiative:[@amp2024]
- Academic partners: Major research universities
- Pharmaceutical companies: Eli Lilly, Genentech, AstraZeneca, others
- Patient organizations: Alzheimer's Association
- NIH: NIA, NINDS
Goals
The consortium aims to:[@gauth2018]
- Identify novel drug targets
- Validate existing targets
- Develop biomarkers
- De-risk clinical trials
Key Datasets
Transcriptomics
RNA-seq from multiple brain regions:[@swarup2017]
- Prefrontal cortex
- Temporal cortex
- Hippocampus
- Dorsolateral striatum
- Cerebellum
Proteomics
Mass spectrometry-based proteomics:
- Quantitation of thousands of proteins
- Phosphoproteomics
- Acetylomics
Metabolomics
Metabolite profiling:
- Brain tissue metabolomics
- CSF metabolomics
- Plasma metabolomics
Genomics
Integration with:
- GWAS summary statistics
- Whole exome sequencing
- Expression quantitative trait loci (eQTLs)
Study Cohorts
Religious Orders Study (ROS)
- Nuns and monks
- annual cognitive assessments
- brain donation
Memory and Aging Project (MAP)
- Community-dwelling adults
- longitudinal cognitive data
- multimodal biomarkers
Additional Cohorts
- Banner-Sun Health
- viu-Mainz
- MassGeneral Institute
- University of Kentucky
Major Findings
Novel Target Identification
AMP-AD has identified numerous novel targets:[@chen2020]
- TREM2: Microglial receptor (validated)
- PLXNA4: Microglial activation
- CD33: Immunomodulatory target
Gene Co-Expression Networks
Network analysis reveals:[@wang2018]
- Dysregulated modules in AD
- Cell-type-specific changes
- Hub genes as potential targets
Multi-Omics Integration
Integrated analysis identifies:[@brase2016]
- Concordant changes across modalities
- Novel gene-disease relationships
- Biomarker candidates
Network-Based Drug Repositioning
Computational approaches have identified:[@tian2021]
- Existing drugs with AD therapeutic potential
- Mechanism of action predictions
- Clinical trial candidates
APOE4 Effects
Studies show:[@barnes2022]
- Sex-specific APOE4 effects
- Interaction with tau pathology
- Therapeutic implications
Impact on Drug Discovery
Target Validation
AMP-AD data support:
- Genetic validation of targets
- Biomarker development
- Clinical trial enrichment
De-Risking
The consortium helps reduce failure risk by:
- Understanding target biology
- Identifying patient subsets
- Developing companion diagnostics
Data Sharing
Open data access accelerates:
- Independent analysis
- Method development
- Drug development
Data Access
All data are publicly available:[@amp2024]
- Sage Bionetworks: AMP-AD Knowledge Portal
- Synapse: Data download platform
- Publications: Consortium papers
Cross-Links to Related Pages
Related Diseases
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Mild Cognitive Impairment](/diseases/mild-cognitive-impairment)
Related Genes
- [APOE](/genes/apoe)
- [TREM2](/genes/trem2)
- [CD33](/genes/cd33)
Related Proteins
- [TREM2 Protein](/proteins/trem2-protein)
- [Amyloid Precursor Protein](/proteins/amyloid-precursor-protein)
Related Mechanisms
- [Neuroinflammation](/mechanisms/neuroinflammation)
- [Protein Aggregation](/mechanisms/protein-aggregation)
Related Datasets
- [Religious Orders Study](/datasets/ros-map)
- [UK Biobank](/datasets/uk-biobank)
External Links
- [AMP-AD Official Website](https://www.nia.nih.gov/research/amp-ad)
- [AMP-AD Knowledge Portal](https://synapse.org)
- [NIH Accelerating Medicines Partnership](https://www.nih.gov/amp)
References
Pathway Diagram
The following diagram shows the key molecular relationships involving Accelerating Medicines Partnership Alzheimer's Disease (AMP-AD) discovered through SciDEX knowledge graph analysis:
▸Metadataorigin_type: v1_polymorphic_backfill
| slug | datasets-amp-ad |
| kg_node_id | None |
| entity_type | dataset |
| origin_type | v1_polymorphic_backfill |
| source_table | wiki_pages |
| wiki_page_id | wp-014a01e64a37 |
| __merged_from | {'merged_at': '2026-05-13', 'unprefixed_id': 'datasets-amp-ad'} |
| _schema_version | 1 |
No provenance edges found
Use ?embed=1 to load the artifact without SciDEX chrome — suitable for iframing into wiki pages or external sites.
<iframe src="http://scidex.ai/artifact/wiki-datasets-amp-ad?embed=1" width="100%" height="600" style="border:0;border-radius:8px"></iframe>
[Accelerating Medicines Partnership Alzheimer's Disease (AMP-AD)](http://scidex.ai/artifact/wiki-datasets-amp-ad)
http://scidex.ai/artifact/wiki-datasets-amp-ad